Cannell & Co. Vertex Pharmaceuticals Inc Transaction History
Cannell & Co.
- $3.01 Billion
- Q4 2023
A detailed history of Cannell & Co. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Cannell & Co. holds 1,712 shares of VRTX stock, worth $786,509. This represents 0.02% of its overall portfolio holdings.
Number of Shares
1,712
Previous 1,712
-0.0%
Holding current value
$786,509
Previous $595,000
16.97%
% of portfolio
0.02%
Previous 0.02%
Shares
5 transactions
Others Institutions Holding VRTX
# of Institutions
1,835Shares Held
233MCall Options Held
1.38MPut Options Held
1.08M-
Capital World Investors Los Angeles, CA28.5MShares$13.1 Billion2.34% of portfolio
-
Vanguard Group Inc Valley Forge, PA23.5MShares$10.8 Billion0.21% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$9.79 Billion0.23% of portfolio
-
Capital Research Global Investors Los Angeles, CA14.5MShares$6.68 Billion1.6% of portfolio
-
State Street Corp Boston, MA11.8MShares$5.42 Billion0.24% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $118B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...